HC Wainwright Has Positive Estimate for KYMR FY2029 Earnings

Key Points

• HC Wainwright has raised its FY2029 earnings per share estimate for Kymera Therapeutics to ($3.32) from a previous forecast of ($3.36), maintaining a "Buy" rating with a $70.00 target price.
• Analysts widely support the stock with two rating it as a Strong Buy, seventeen as a Buy, and only one giving it a Hold.
• Kymera Therapeutics has faced challenges, reporting a 55.1% revenue decline from the previous year and missing earnings expectations with an EPS of ($0.95) in its last quarter.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Equities researchers at HC Wainwright raised their FY2029 earnings per share estimates for Kymera Therapeutics in a note issued to investors on Thursday, September 18th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($3.32) per share for the year, up from their previous forecast of ($3.36). HC Wainwright currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share.

Several other analysts also recently issued reports on the company. Bank of America raised Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price target on the stock in a report on Monday, June 2nd. JPMorgan Chase & Co. lifted their target price on Kymera Therapeutics from $57.00 to $64.00 and gave the company an "overweight" rating in a research note on Tuesday, June 3rd. BTIG Research reiterated a "buy" rating and set a $59.00 price target on shares of Kymera Therapeutics in a research report on Thursday, June 26th. The Goldman Sachs Group upgraded Kymera Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 15th. Finally, Barclays began coverage on Kymera Therapeutics in a report on Wednesday, September 17th. They issued an "overweight" rating and a $60.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $59.95.

Kymera Therapeutics Trading Down 4.0%

Shares of NASDAQ KYMR opened at $49.13 on Monday. The company has a market cap of $3.51 billion, a price-to-earnings ratio of -14.16 and a beta of 2.17. Kymera Therapeutics has a 12-month low of $19.44 and a 12-month high of $53.27. The stock's 50 day simple moving average is $43.85 and its 200 day simple moving average is $37.96.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The firm had revenue of $11.48 million during the quarter, compared to analyst estimates of $17.37 million. Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.Kymera Therapeutics's revenue was down 55.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.58) EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Ameriprise Financial Inc. bought a new stake in shares of Kymera Therapeutics during the 4th quarter worth about $344,000. BNP Paribas Financial Markets bought a new stake in shares of Kymera Therapeutics during the 4th quarter worth about $396,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Kymera Therapeutics by 7.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,960 shares of the company's stock worth $1,163,000 after acquiring an additional 2,011 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Kymera Therapeutics by 205.0% during the 4th quarter. Millennium Management LLC now owns 115,918 shares of the company's stock worth $4,663,000 after acquiring an additional 77,912 shares in the last quarter. Finally, Nuveen Asset Management LLC boosted its stake in shares of Kymera Therapeutics by 2.2% during the 4th quarter. Nuveen Asset Management LLC now owns 143,225 shares of the company's stock worth $5,762,000 after acquiring an additional 3,038 shares in the last quarter.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the transaction, the chief executive officer owned 660,482 shares in the company, valued at $32,363,618. The trade was a 4.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Bruce N. Jacobs sold 79,220 shares of the business's stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $50.00, for a total value of $3,961,000.00. Following the completion of the transaction, the chief financial officer owned 227,409 shares in the company, valued at $11,370,450. This trade represents a 25.84% decrease in their position. The disclosure for this sale can be found here. 16.01% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.